Biotech Archives - Page 25 of 733

2 minute read

This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan

May 21, 10:41 PM

The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.

BHVN

2 minute read

EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic

By Piero Cingari

May 21, 4:33 PM

Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."

AMGN

1 minute read

Nanobiotix Reports Updates For Global NBTXR3 Development Collaboration Highlighting Robust Pipeline And Pathway To Long-Term Growth

By Benzinga Newsdesk

May 21, 4:20 PM

Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3Alignment of intent to transfer the sponsorship of the ongoing

NBTX

1 minute read

Neurocrine Biosciences Phase 3 KINECT-4 Post Hoc Analysis Demonstrates Clinically Meaningful And Sustained Improvement In Tardive Dyskinesia With Long-Term Use Of INGREZZA Capsules

By Benzinga Newsdesk

May 21, 4:14 PM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA&r

NBIX

2 minute read

Larimar Therapeutics’ Friedreich’s Ataxia Investigational Drug Differentiated From Biogen’s Marketed Drug

By Vandana Singh

May 21, 2:39 PM

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin level increases.

BIIB

2 minute read

Weight Loss Drugs Like Wegvoy and Zepbound Users – Nestlé Launches $5 Pizza For You

By Vandana Singh

May 21, 2:25 PM

Nestlé SA launches Vital Pursuit, a new food line tailored for GLP-1 weight loss medication users, featuring protein, fiber, and essential nutrients. Available Q4 nationwide.

LLY

2 minute read

Citius Pharma’s ‘Antibiotic Lock’ Effective In Patients With Catheter-Associated Bloodstream Infections

By Vandana Singh

May 21, 1:40 PM

Citius Pharmaceuticals' Phase 3 trial results for Mino-Lok, an antibiotic lock solution for central line-associated infections, show significant improvement in time to catheter failure and overall treatment success.

CTXR

2 minute read

GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims

By Vandana Singh

May 21, 12:48 PM

Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen, prompting a whistleblower lawsuit seeking billions in damages.

GSK

1 minute read

RenovoRx Announces Publication Of Results Of Pre-Clinical Studies Support Efficacy And Drug Delivery Mechanism Potential Of The Co’s TAMP Therapy Platform To Improve Targeted Cancer Drug Treatment Delivery

By Benzinga Newsdesk

May 21, 9:36 AM

Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapyTAMP offers the potential to

RNXT

2 minute read

Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide

By Vandana Singh

May 21, 9:36 AM

Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1 agonists are poised to drive a $2 billion market by 2030.

LLY